Guggenheim cuts Neurocrine Bio. stock target to $163
Guggenheim maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowered the price target to $163 from $165. The adjustment follows the company's fourth-quarter sales report, which ...
Cornwall Live on MSN18m
'Most likable, loveable, kind person' died while receiving 'inadequate' care
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...